AlphaMadera
Medpace Holdings, Inc. (MEDP)
$672.93
+1.20 (+0.18%)Delayed quote.
Price history
Daily close- Start
- $600.44
- Latest close
- $672.93
- Period change
- +12.07%
- Period low
- $393.42
- Period high
- $692.68
Key metrics
- Market cap
- $18.30B
- Volume
- 5.3K
- Average volume
- 289.2K
- 52-week range
- $373.00 – $693.97
- Beta
- 1.12
- Last dividend
- —
- EPS (TTM)
- $18.36
- P/E ratio
- 36.65
- Revenue (TTM)
- $2.84B
- Net income (TTM)
- $517.83M
- Total assets
- $2.30B
- Total debt
- $146.04M
- Cash and equivalents
- $705.32M
Key financials (trailing twelve months).
Company profile
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Exchange
- NASDAQ
- CEO
- August James Troendle
- Employees
- 6,600
- Headquarters
- Cincinnati, OH, US
- IPO date
- 2016-08-11
- Website
- https://www.medpace.com
Financial statements
Annual, last 3 fiscal years. Most recent period first. Reported in USD.
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Revenue | $2.53B | $2.11B | $1.89B |
| Gross profit | $760.62M | $656.30M | $524.50M |
| Operating income | $534.93M | $446.87M | $336.82M |
| EBITDA | $570.50M | $505.17M | $362.50M |
| Net income | $451.12M | $404.39M | $282.81M |
| Diluted EPS | $15.28 | $12.63 | $8.88 |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $497.05M | $669.44M | $245.45M |
| Total assets | $1.98B | $2.10B | $1.66B |
| Total liabilities | $1.52B | $1.28B | $1.10B |
| Total debt | $136.85M | $149.52M | $164.49M |
| Shareholders’ equity | $459.07M | $825.54M | $558.95M |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | $713.22M | $608.82M | $433.37M |
| Capital expenditure | -$31.36M | -$36.55M | -$36.65M |
| Free cash flow | $681.87M | $572.27M | $396.73M |
Quarterly, last 6 quarters. Most recent period first. Reported in USD.
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Revenue | $716.00M | $707.33M | $706.60M | $708.45M | $659.90M | $603.31M |
| Gross profit | $223.88M | $201.64M | $196.33M | $205.32M | $196.94M | $180.01M |
| Operating income | $165.54M | $146.82M | $141.50M | $153.27M | $141.81M | $126.33M |
| EBITDA | $177.49M | $147.60M | $154.50M | $163.96M | $149.88M | $131.55M |
| Net income | $137.46M | $121.36M | $123.87M | $135.13M | $111.14M | $90.26M |
| Diluted EPS | $4.84 | $4.25 | $4.28 | $4.67 | $3.87 | $3.10 |
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $705.32M | $502.69M | $652.68M | $497.05M | $285.35M | $46.33M |
| Total assets | $2.30B | $2.06B | $2.13B | $1.98B | $1.75B | $1.57B |
| Total liabilities | $1.72B | $1.62B | $1.53B | $1.52B | $1.46B | $1.40B |
| Total debt | $146.04M | $144.11M | $146.09M | $136.85M | $143.97M | $149.83M |
| Shareholders’ equity | $584.94M | $433.86M | $598.31M | $459.07M | $293.64M | $172.35M |
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $216.60M | $162.01M | $151.79M | $192.65M | $246.21M | $148.53M |
| Capital expenditure | -$20.16M | -$23.91M | -$6.81M | -$4.54M | $16.11M | -$6.11M |
| Free cash flow | $196.44M | $138.10M | $144.97M | $188.12M | $262.32M | $142.41M |